Evaluating the Effects of Platelet-Rich Plasma and Amniotic Viscous Fluid on Inflammatory Markers in a Human Coculture Model for Osteoarthritis

O’Brien, Daniel R.; Kia, Cameron; Beebe, Roy; Macken, Craig; Bell, Ryan; Cote, Mark P.; McCarthy, Mary-Beth; Williams, Vincent; Mazzocca, Augustus D.

doi:10.1016/j.arthro.2019.03.021

Cited by 13 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Recent favorable outcomes of PRP treatment suggest that despite the initial critique, PRP may have set the bar too high for all other biological treatments. In the study of O'Brien et al, 6 PRP appears to be more consistent in its anti-inflammatory effect than amniotic fluid. The minimal morbidity of blood drawn when using autologous PRP seems to outweigh the risks from allogeneic tissue administration at the moment.…”

Section: Effectivenessmentioning

confidence: 86%

“…The use of platelet-rich plasma (PRP) and other biological agents in treating orthopaedic conditions has attracted the interest of the research community, and recent studies with high levels of evidence have supported PRP use, showing clinically significant functional improvement 12 months after injection. 4,5 In the study "Evaluating the Effects of Platelet-Rich Plasma and Amniotic Viscous Fluid on Inflammatory Markers in a Human Co-culture Model for Osteoarthritis," O'Brien, KC, Beebe, McCarthy, Cote, Macken, Bell, Williams, and Mazzocca 6 presented their findings on the anti-inflammatory effect of PRP and amniotic viscous fluid in an in vitro human co-culture model of osteoarthritic cartilage and synovium. Their work is novel in evaluating the anti-inflammatory effect of amniotic viscous fluid in vitro.…”

Section: See Related Article On Page 2421mentioning

confidence: 99%

“…This study showed that PRP and amniotic fluid were overall effective in reducing ADAMTS5 and TIMP1 gene expression and increasing ACAN and type I collagen gene expression in cartilage and in synovium, suggesting their anti-inflammatory and pro-cartilaginous profile, respectively. O'Brien et al 6 also indicated that amniotic products were less consistent in reducing inflammation compared with PRP and that there was no significant additive anti-inflammatory effect. This finding may suggest that both agents use the same pathway to reduce inflammation.…”

Section: See Related Article On Page 2421mentioning

confidence: 99%

See 2 more Smart Citations

Editorial Commentary: Could Biological Treatments Be the Game-Changing Factor for Osteoarthritis?

Paschos¹

2019

Arthroscopy: The Journal of Arthroscopic & Related Surgery

View full text Add to dashboard Cite

The realization of the presence of an inflammatory component in cartilage degeneration together with the promising application of platelet-rich plasma and amnion as "healing agents" opened a new window of opportunity for biological treatments in osteoarthritis. If the goal is to delay or even cease the degenerative process, then treating the cause rather than the symptom is a key factor for this biological intervention to be successful. As new biological agents arise, there are 3 crucial milestones that need to be met in laboratory and clinical studies: safety, reasonable cost, and improved effectiveness in comparison with alternatives.

show abstract

Section: Effectivenessmentioning

confidence: 86%

Section: See Related Article On Page 2421mentioning

confidence: 99%

Section: See Related Article On Page 2421mentioning

confidence: 99%

See 1 more Smart Citation

Editorial Commentary: Could Biological Treatments Be the Game-Changing Factor for Osteoarthritis?

Paschos¹

2019

Arthroscopy: The Journal of Arthroscopic & Related Surgery

View full text Add to dashboard Cite

show abstract

“…In OA research, these are often derived from cow, but also horse, dog or sheep ( Greenberg et al, 2006 ; Lee et al, 2013 ; Byron and Trahan, 2017 ; Swärd et al, 2017 ; Haltmayer et al, 2019 ; Mehta et al, 2019 ), and also human explants gained importance in OA research ( Table 3 ) ( Hardy et al, 2002 ; Schwab et al, 2017 ; Geurts et al, 2018 ; Topoluk et al, 2018 ; Favero et al, 2019 ; Houtman et al, 2021a ; Houtman et al, 2021b ). Cartilage tissue co-culture models mainly comprise explants of cartilage combined with primary cells or other joint components, such as the attached subchondral bone ( Byron and Trahan, 2017 ; Schwab et al, 2017 ) synovium ( Hardy et al, 2002 ; O'Brien et al, 2019 ; Osterman et al, 2015 ; Araújo et al, 2020 ) or joint capsule ( Swärd et al, 2017 ), the infrapatellar fat pad ( Nishimuta et al, 2017 ) or nervous tissue ( Li et al, 2011 ) ( Figures 4 , 5A ).…”

Section: Co-cultured Tissue Explantsmentioning

confidence: 99%

The Added Value of the “Co” in Co-Culture Systems in Research on Osteoarthritis Pathology and Treatment Development

Muenzebrock

Kersten

Alblas

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Osteoarthritis (OA) is a highly prevalent disease and a major health burden. Its development and progression are influenced by factors such as age, obesity or joint overuse. As a whole organ disease OA affects not only cartilage, bone and synovium but also ligaments, fatty or nervous tissue surrounding the joint. These joint tissues interact with each other and understanding this interaction is important in developing novel treatments. To incorporate and study these interactions in OA research, several co-culture models have evolved. They combine two or more cell types or tissues and investigate the influence of amongst others inflammatory or degenerative stimuli seen in OA. This review focuses on co-cultures and the differential processes occurring in a given tissue or cell as a consequence of being combined with another joint cell type or tissue, and/or the extent to which a co-culture mimics the in vivo processes. Most co-culture models depart from synovial lining and cartilage culture, but also fat pad and bone have been included. Not all of the models appear to reflect the postulated in vivo OA pathophysiology, although some of the discrepancies may indicate current assumptions on this process are not entirely valid. Systematic analysis of the mutual influence the separate compartments in a given model exert on each other and validation against in vivo or ex vivo observation is still largely lacking and would increase their added value as in vitro OA models.

show abstract

“…Indeed, human amniotic products have a broad immune mediating profile [5]. Human amniotic membrane (hAM) and human amniotic fluid (hAF) have been shown to reduce inflammation, have antimicrobial properties, and confer a low risk of immunogenicity [6][7][8][9][10][11]. Purified hAF is non-antigenic solution devoid of any cellular products (i.e., it is not to be confused with umbilical cord-derived, AF-derived stem cell products, or AF embolism) that nature developed [5,12].…”

Section: Introductionmentioning

confidence: 99%

A pilot trial of human amniotic fluid for the treatment of COVID-19

et al. 2021

View full text Add to dashboard Cite

Objective Vertical transmission from SARS CoV-2-infected women is uncommon and coronavirus has not been detected in amniotic fluid. Human amniotic products have a broad immune-mediating profile. Observing that many COVID-19 patients have a profound inflammatory response to the virus, we sought to determine the influence of human amniotic fluid (hAF) on hospitalized patients with COVID-19. Results A 10-patient case series was IRB-approved to study the impact of hAF on hospitalized patients with documented COVID-19. Nine of the 10 patients survived to discharge, with one patient succumbing to the disease when enrolled on maximal ventilatory support and severe hypoxia. The study design was altered by the IRB such that the last 6 patients received higher dose of intravenous hAF. In this latter group, patients that had observed reductions in C-reactive protein were associated with improved clinical outcomes. No hAF-related adverse events were noted. Acknowledging some of the inherent limitations of this case series, these results inform and catalyze a larger scaled randomized prospective trial to further investigate hAF as a therapy for COVID-19. Trial Registration ClinicalTrials.gov: NCT04319731; March 23, 2020

show abstract

Evaluating the Effects of Platelet-Rich Plasma and Amniotic Viscous Fluid on Inflammatory Markers in a Human Coculture Model for Osteoarthritis

Cited by 13 publications

References 30 publications

Editorial Commentary: Could Biological Treatments Be the Game-Changing Factor for Osteoarthritis?

Editorial Commentary: Could Biological Treatments Be the Game-Changing Factor for Osteoarthritis?

The Added Value of the “Co” in Co-Culture Systems in Research on Osteoarthritis Pathology and Treatment Development

A pilot trial of human amniotic fluid for the treatment of COVID-19

Contact Info

Product

Resources

About